Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Decitabine limits escape from MEK inhibition in uveal melanoma

Decitabine limits escape from MEK inhibition in uveal melanoma MEK inhibitors (MEKi) demonstrate anti‐proliferative activity in patients with metastatic uveal melanoma, but responses are short‐lived. In the present study, we evaluated the MEKi trametinib alone and in combination with drugs targeting epigenetic regulators, including DOT1L, EZH2, LSD1, DNA methyltransferases, and histone acetyltransferases. The DNA methyltransferase inhibitor (DNMTi) decitabine effectively enhanced the anti‐proliferative activity of trametinib in cell viability, colony formation, and 3D organoid assays. RNA‐Seq analysis showed the MEKi‐DNMTi combination primarily affected the expression of genes involved in G1 and G2/2M checkpoints, cell survival, chromosome segregation and mitotic spindle. The DNMTi‐MEKi combination did not appear to induce a DNA damage response (as measured by γH2AX foci) or senescence (as measured by β‐galactosidase staining) compared to either MEKi or DNMTi alone. Instead, the combination increased expression of the CDK inhibitor p21 and the pro‐apoptotic protein BIM. In vivo, the DNMTi‐MEKi combination was more effective at suppressing growth of MP41 uveal melanoma xenografts than either drug alone. Our studies indicate that DNMTi may enhance the activity of MEKi in uveal melanoma. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pigment Cell & Melanoma Research Wiley

Loading next page...
 
/lp/wiley/decitabine-limits-escape-from-mek-inhibition-in-uveal-melanoma-5q4hJcbz3e

References (25)

Publisher
Wiley
Copyright
Copyright © 2020 John Wiley & Sons A/S
ISSN
1755-1471
eISSN
1755-148X
DOI
10.1111/pcmr.12849
Publisher site
See Article on Publisher Site

Abstract

MEK inhibitors (MEKi) demonstrate anti‐proliferative activity in patients with metastatic uveal melanoma, but responses are short‐lived. In the present study, we evaluated the MEKi trametinib alone and in combination with drugs targeting epigenetic regulators, including DOT1L, EZH2, LSD1, DNA methyltransferases, and histone acetyltransferases. The DNA methyltransferase inhibitor (DNMTi) decitabine effectively enhanced the anti‐proliferative activity of trametinib in cell viability, colony formation, and 3D organoid assays. RNA‐Seq analysis showed the MEKi‐DNMTi combination primarily affected the expression of genes involved in G1 and G2/2M checkpoints, cell survival, chromosome segregation and mitotic spindle. The DNMTi‐MEKi combination did not appear to induce a DNA damage response (as measured by γH2AX foci) or senescence (as measured by β‐galactosidase staining) compared to either MEKi or DNMTi alone. Instead, the combination increased expression of the CDK inhibitor p21 and the pro‐apoptotic protein BIM. In vivo, the DNMTi‐MEKi combination was more effective at suppressing growth of MP41 uveal melanoma xenografts than either drug alone. Our studies indicate that DNMTi may enhance the activity of MEKi in uveal melanoma.

Journal

Pigment Cell & Melanoma ResearchWiley

Published: May 1, 2020

Keywords: ; ; ; ;

There are no references for this article.